BriaCell Therapeutics (BCTX) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

BCTX · Stock Price

USD 4.10-27.00 (-86.82%)

Market Cap: $29.5M

Historical price data

Overview

BriaCell Therapeutics is a clinical-stage biotech focused on developing targeted cellular immunotherapies to transform cancer care. Its core strategy is advancing Bria-IMT™, a Fast Track-designated candidate in a pivotal Phase 3 study for metastatic breast cancer, while expanding its pipeline through the innovative Bria-OTS™ platform, which enables personalized, off-the-shelf treatments. The company has demonstrated promising clinical data, including extended survival in heavily pre-treated patients, and is backed by collaborations with the National Cancer Institute.

OncologyImmuno-oncology

Technology Platform

A proprietary off-the-shelf cellular immunotherapy platform using irradiated, engineered allogeneic cell lines designed to act as in-situ cancer vaccines, with a next-generation (Bria-OTS™) variant enabling HLA-matched personalization for over 99% of patients.

Pipeline

4

4 drugs in pipeline1 in Phase 3

Drug	Indication	Stage
SV-BR-1-GM + Cyclophosphamide + Interferon infiltration of t...	Breast Cancer	Phase 3
SV-BR-1-GM + Low dose cyclophosphamide + Interferon Inoculat...	Breast Cancer	Phase 1/2
BC1 cell line + Bria-OTS regimen and CPI (tislelizumab) + Br...	Breast Cancer	Phase 1/2
SV-BR-1-GM + Cyclophosphamide + Interferon-alpha-2b	Breastcancer	Phase 1/2

Opportunities

Bria-IMT™ addresses a high-unmet need in late-line metastatic breast cancer, particularly in patients with CNS metastases and those resistant to ADCs.

The Bria-OTS™ platform, if validated, could enable rapid expansion into large solid tumor markets like prostate and lung cancer with a personalized yet off-the-shelf product.

Risk Factors

The company faces binary clinical risk from its pivotal Phase 3 trial and requires substantial additional capital to complete development.

It operates in an intensely competitive oncology landscape against larger players with more resources and advanced therapies.

Competitive Landscape

BriaCell competes with other off-the-shelf cell therapy developers (e.g., Fate Therapeutics), personalized cancer vaccine companies (e.g., BioNTech, Moderna), and established breast cancer therapeutics. Its key differentiator is the combination of an off-the-shelf format with HLA-based personalization via a pre-manufactured cell library.

More companies in Immunotherapy / Immuno-Oncology →More companies in United States →